For Immediate Release

Chicago, IL - May 11, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Osiris Therapeutics, Inc. (OSIR), Genzyme Corp. (GENZ), Barclays PLC (BCS), Intersil Corporation (ISIL) and Isis Pharmaceuticals (ISIS).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Friday's Analyst Blog:

Optimistic on Osiris

Osiris Therapeutics, Inc. (OSIR) reported financial results for the first quarter 2009 on May 7, 2009. Total revenues in the quarter were $12.7 million, up from $0.4 million for the same period for 2008, and slightly above our forecasts of

...

We highlight Osiris Therapeutics, Inc. (OSIR) and Genzyme Corp. (GENZ).Osiris Therapeutics, Inc. (OSIR) reported financial results for the first quarter 2009 on May 7, 2009. Total revenues in the quarter were $12.7 million, up from $0.4 million for the same period for 2008, and slightly above our forecasts of $11.8 million.Revenues include the recognition of $10.0 million in amortized license fees from Genzyme Corp. (GENZ) and $2.6 million related to the contract with the U.S. Department of Defense. The company reported net income of $14.8 million, or $0.45 per share for the quarter. This figure is comprised of losses from continuing operations of $7.9 million, or $0.24 per share, and income from discontinued operations of $22.7 million, or $0.69 per share.Osiris exited the first quarter with $55.0 million in cash and $79.7 million in accounts receivable. Working capital totaled $123.5 ...

Highlights include Osiris Therapeutics, Inc. (OSIR) and Genzyme Corp. (GENZ).Management Halts Phase III Crohn's Trial Due to Design FlawOn March 27, 2009, Osiris Therapeutics (OSIR) announced it was stopping its phase III clinical trial program testing Prochymal for the treatment of acute Crohn's disease (CD) due to a design flaw in the trial that was allowing for significantly higher-than-expected placebo response rates.The decision was made after the trial's final scheduled interim analysis showed that 1 of the 2 Prochymal dose arms had crossed a futility boundary (would not achieve statistical significance).As a reminder, Osiris' phase III CD program consisted of 2 trials, and induction program (S-603) followed by a maintenance program (S-610). The Study-603 "Induction" program was targeted to enroll 270 patients and randomize into three arms, one-high dose Prochymal, one low-dose Prochymal and placebo.After 28 ...

Talk about a no brainer, Citigroup Inc. (NYSE: C) was beaten down to the one dollar range, so it had no place to go but up. Add to that two sure fire buy signals, a huge short interest that had to start short covering and the fact that banks are getting blank checks from their favorite uncle, and you have a classic powder keg. Citi is already nearing a triple from its lows. It’s these types of returns that have investors asking, “Where are the next opportunities?”

While the banks will be the biggest beneficiaries, by far, they’re not the only beneficiaries of the federal funds free for all. Investors can still pick up bargains in alternative energy, infrastructure and technology stocks, which are all expected to be the next President Obama plays. The technology plays range from Warren Buffet’s latest pick, Nalco Holding (NYSE: NLC), a water treatment technology

...

a onblur=”try {parent.deselectBloggerImageGracefully();} catch(e) {}” href=”http://2.bp.blogspot.com/_T9VXVyuEITg/SYksOvCIT5I/AAAAAAAAAoM/DrrO_JiQPJ8/s1600-h/stem_cells.jpg”img style=”float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 200px; height: 169px;” src=”http://2.bp.blogspot.com/_T9VXVyuEITg/SYksOvCIT5I/AAAAAAAAAoM/DrrO_JiQPJ8/s200/stem_cells.jpg” border=”0″ alt=”"id=”BLOGGER_PHOTO_ID_5298815068233289618″ //abr /Since President Obama has decided to repeal the limitations imposed on embryonic stem cell research, and since the first federally approved human study utilizing embryonic stem cell therapy is now taking place, investors are now looking at opportunities in stem cell stocks. Extensive research is being done to utilize stem cells for a href=”http://stockerblog.blogspot.com/2008/05/gene-therapy-stocks.html” target-”_blank”gene therapy/a and the treatment of multiple sclerosis, Parkinson’s disease, heart disease, diabetes, arthritis, and many other medical conditions. br /br /A source of stem cells is a href=”http://cordbloodstocks.com/” target-”_blank”cord blood/a, the blood from an umbilical cord. The saving and storing of cord blood has become a fast growing business. For example, Richard Branson, founder and head of Virgin Records and Virgin Atlantic Airways, set up a cord blood bank. Even a href=”http://stockerblog.blogspot.com/2007/10/stem-cell-bonds-issued-by-california.html” target-”_blank”Stem Cell …